Calmare Therapuetics Incorporated., (OTCQX: CTTC) Distributor of Calmare--a non-invasive and non-narcotic chronic pain management medical device with FDA 510K Marketing Allowance
CTTC Corporate Website: http://www.calmaretherapeutics.com
Calmare Website: www.calmarett.com
CTTC FACEBOOK Page: https://www.facebook.com/Competitivetech
US Navy, US Army, US Air Force and VA Hospitals utilizing Calmare for Chronic Pain Management MAYO CLINIC News on Calmare (November, 2014) http://www.reuters.com/video/2014/09/30/scrambling-away-pain-for-cancer-patients?videoId=346379225&videoChannel=6
TV News Report on Calmare
US Government Medical Institutions Using Calmare
Andrews Air Force Base
TV News Report Calmare technology and patient testimonial (http://www.ksl.com/?nid=148&sid=16580318).
Deseret News article: (http://www.deseretnews.com/article/705388446/Device-used-by-southern-Utah-doctor-is-helping-people-live-a-life-without-constant-pain.html) highlighted the success Dr. Robert Chalmers of Utah had in treatment of a teenager who had suffered from severe pain from a nerve disorder called reflex neurovascular dystrophy, or RND, for nearly two years.
- Calmare is a medical device that treats Chronic Pain Patients, FDA and CE approved
116 million people experience Chronic Pain in the US.
There are independently initiated clinical trials at the Mayo, University of Wisconsin, Massey Cancer Center and Johns Hopkins to validate the significant results that have been observed.
Calmare Specific Treatment Indications for Chronic Pain Include:
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Intractable Cancer Pain
Failed Back Surgery Syndrome
Sciatic and Lumbar Pain
Post Herpetic Neuralgia
Brachial Plexus Pain
Low Back Pain
Chronic Neuropathic Pain
Recently Published Clinical Trial Results (Jan. 2015)
Res Nurs Health. 2015 Jan 8. doi: 10.1002/nur.21632
Decreased Low Back Pain Intensity and Differential Gene Expression Following Calmare®: Results From a Double-Blinded Randomized Sham-Controlled Study.
Starkweather AR1, Coyne P, Lyon DE, Elswick RK Jr, An K, Sturgill J.
1Associate Professor and Chair Department of Adult Health and Nursing Systems,
Virginia Commonwealth University School of Nursing
1100 East Leigh Street
P.O. Box 980567
Richmond, VA 23298-0567.
In this double-blinded, randomized controlled trial we evaluated the effects of Calmare®, a non-invasive neurocutaneous electrical pain intervention, on lower back pain intensity as measured by the "worst" pain score and on pain interference using the Brief Pain Inventory-Short Form, on measures of pain sensitivity assessed by quantitative sensory testing, and on mRNA expression of pain sensitivity genes. Thirty participants were randomized to receive up to 10 sessions of Calmare® treatment (n?=?15) or a sham treatment (n?=?15) using the same device at a non-therapeutic threshold.
At 3 weeks after conclusion of treatment, compared with the sham group, the Calmare® group reported a significant decrease in the "worst" pain and interference scores. There were also significant differences in pain sensitivity and differential mRNA expression of 17 pain genes, suggesting that Calmare® can be effective in reducing pain intensity and interference in individuals with persistent low back pain by altering the mechanisms of enhanced pain sensitivity.
Further study of long-term pain outcomes, particularly functional status, analgesic use and health care utilization, is warranted. © 2015 Wiley Periodicals, Inc.
© 2015 Wiley Periodicals, Inc.
Calmare®; chronic pain; gene expression; low back pain; scrambler
PMID: 25572279 [PubMed - as supplied by publisher]Decreased Low Back Pain Intensity and Differential Gene Expression ... - PubMed - NCBI